Precision radiation meets new drugs in fight against brain metastases from melanoma

NCT ID NCT07691255

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at how a highly targeted form of radiation called stereotactic radiosurgery (CyberKnife) works alongside newer treatments like immunotherapy and targeted therapy for people with melanoma that has spread to the brain. Researchers will observe 50 patients over time to see how long the treated brain tumors stay under control and how the timing of treatments affects outcomes. The goal is to help doctors design better treatment plans for this challenging condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
stereotactic radiosurgery (CyberKnife)
What this could lead to
If successful, this could help doctors choose the best timing and combination of radiation and newer drugs to better control melanoma that has spread to the brain.
What could go wrong
This is an observational study with only 50 patients, so results may not apply to everyone. It does not test a new treatment directly, and outcomes depend on many factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • European Institute of Oncology, Milan

    Milan, Mi, 20141, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.